Eversept Partners LP Purchases 93,882 Shares of Ionis Pharmaceuticals, Inc. $IONS

Eversept Partners LP raised its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 17.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 632,100 shares of the company’s stock after acquiring an additional 93,882 shares during the period. Ionis Pharmaceuticals makes up 2.5% of Eversept Partners LP’s portfolio, making the stock its 10th biggest position. Eversept Partners LP’s holdings in Ionis Pharmaceuticals were worth $47,464,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in shares of Ionis Pharmaceuticals by 548.7% in the 4th quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock worth $2,643,000 after purchasing an additional 28,259 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ionis Pharmaceuticals by 51.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 42,394 shares of the company’s stock worth $3,354,000 after purchasing an additional 14,455 shares during the period. J. Safra Sarasin Holding AG acquired a new stake in Ionis Pharmaceuticals during the 4th quarter worth approximately $1,377,000. Franklin Resources Inc. increased its position in Ionis Pharmaceuticals by 19,941.6% during the 4th quarter. Franklin Resources Inc. now owns 1,321,345 shares of the company’s stock worth $104,532,000 after purchasing an additional 1,314,752 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its holdings in Ionis Pharmaceuticals by 216.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock valued at $141,753,000 after buying an additional 1,225,043 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 50,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $80.59, for a total value of $4,029,500.00. Following the transaction, the chief executive officer owned 245,571 shares in the company, valued at $19,790,566.89. The trade was a 16.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eugene Schneider sold 26,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $81.05, for a total transaction of $2,107,300.00. Following the completion of the transaction, the executive vice president owned 77,114 shares in the company, valued at $6,250,089.70. This represents a 25.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 233,163 shares of company stock valued at $18,316,551. Corporate insiders own 1.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IONS. Needham & Company LLC decreased their price objective on shares of Ionis Pharmaceuticals from $105.00 to $86.00 and set a “buy” rating for the company in a research note on Thursday, July 9th. Bank of America raised their target price on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Barclays reduced their target price on shares of Ionis Pharmaceuticals from $115.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, July 10th. Morgan Stanley decreased their price target on shares of Ionis Pharmaceuticals from $130.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada cut their price objective on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Eighteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $95.90.

Ionis Pharmaceuticals Stock Down 1.0%

NASDAQ IONS opened at $55.96 on Tuesday. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $40.03 and a fifty-two week high of $86.74. The business has a 50 day moving average price of $71.27 and a two-hundred day moving average price of $75.31. The stock has a market cap of $9.25 billion, a PE ratio of -27.03 and a beta of 0.36.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The company had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. During the same quarter last year, the firm posted ($0.93) earnings per share. The business’s quarterly revenue was up 86.4% on a year-over-year basis. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.76 EPS for the current fiscal year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.